Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A Micron five-year double thesis focused on HBM demand, DRAM/NAND cycle discipline, capital intensity, and whether AI memory improves through-cycle economics.
Tag facets appear after tag usage counts are rebuilt.
A refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenA TSMC five-year double thesis focused on advanced-node foundry leadership, advanced packaging, AI customer demand, capex, margins, and Taiwan risk.
OpenA Coverage Bootstrap TSMC company evaluation covering advanced-node foundry leadership, CoWoS, customers, margins, capex, global fabs, Taiwan risk, and valuation setup.
OpenA filing-led NVDA five-year double thesis focused on data-center demand, CUDA lock-in, networking attach, margin durability, and valuation risk.
OpenA Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenA Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenA Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenAn ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenA Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAmerican Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII kee
OpenAIG is now a focused global P&C underwriting and capital-return story. The latest filings show a 90.1 General Insurance combined ratio in 2025, an 87.3 combined ratio in Q1 2026, heavy buybacks, a smaller Corebridge stake and a live CEO transition.
OpenAssured Guaranty is a financial guaranty insurer with Q1 2026 new-business growth, record adjusted book value per share and a long buyback record, but the equity case still depends on ratings strength, insured-credit losses, PREPA and disciplined capital alloc
OpenAflac is a high-return supplemental insurer with a real capital-return engine, but its quality case still depends on Japan premium trends, yen translation, regulatory capital and investment marks.
OpenAmerican Financial Group's Q1 2026 specialty P&C engine produced a 90.3% combined ratio and $206 million of core net operating earnings, but the thesis still depends on reserve quality, catastrophe control and disciplined capital returns.
OpenAeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.